Frequency Therapeutics Inc

NASDAQ:FREQ   3:59:53 PM EDT
6.74
-0.11 (-1.61%)
Products

Frequency Therapeutics Releases New Data From Two FX-322 Clinical Studies Plans To Advance Single-Dose Regimen

Published: 03/23/2021 11:19 GMT
Frequency Therapeutics Inc (FREQ) - Frequency Therapeutics Releases New Data From Two Fx-322 Clinical Studies; Plans to Advance Single-dose Regimen.
Frequency Therapeutics Inc - Interim Fx-322 Phase 2a Results Show Four Injection Schedule Had No Discernible Hearing Benefit.
Frequency Therapeutics Inc - Separate Fx-322 Phase 1b Study Confirms Hearing Improvement From Single Injection.
Frequency Therapeutics Inc - No Treatment-related Serious Adverse Events Were Observed in Fx-322 Phase 2a Study.